D. E. Shaw & Co., Inc. Madrigal Pharmaceuticals, Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $1.89 Million - $2.61 Million	8,900 Added 19.82%	53,800 $11.4 Million
Q2 2024 Aug 14, 2024	SELL	$193.33 - $291.99 $1.53 Million - $2.31 Million	-7,900 Reduced 14.96%	44,900 $12.6 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $3.14 Million - $5.18 Million	18,300 Added 53.04%	52,800 $14.1 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $1.2 Million - $2.37 Million	10,000 Added 40.82%	34,500 $7.98 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $3.02 Million - $4.67 Million	20,700 Added 544.74%	24,500 $3.58 Million
Q1 2023 May 15, 2023	BUY	$231.06 - $307.08 $878,028 - $1.17 Million	3,800 New	3,800 $920,000
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $947,700 - $2.16 Million	10,000 Added 263.16%	13,800 $1.56 Million
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $787,740 - $1.14 Million	3,800 New	3,800 $814,000

295

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.02B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.